Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | EPIX |
---|---|---|
09:32 ET | 194 | 6.24 |
09:39 ET | 4300 | 6.105 |
09:43 ET | 5000 | 6.105 |
09:50 ET | 5000 | 6.105 |
09:54 ET | 100 | 6 |
10:46 ET | 1994 | 5.9999 |
10:50 ET | 100 | 5.99 |
10:57 ET | 600 | 5.98 |
11:00 ET | 1297 | 5.99 |
11:04 ET | 2000 | 6.06 |
11:20 ET | 661 | 6.0923 |
11:22 ET | 400 | 6.04 |
11:24 ET | 600 | 6.05 |
11:26 ET | 165 | 6.1129 |
11:49 ET | 500 | 6.08 |
11:54 ET | 125 | 6.05 |
12:30 ET | 100 | 6.12 |
12:36 ET | 1500 | 6.03 |
12:48 ET | 135 | 6.02 |
01:26 ET | 100 | 6.15 |
01:50 ET | 100 | 6.22 |
03:27 ET | 5000 | 6.135 |
03:34 ET | 600 | 6.25 |
03:38 ET | 2000 | 6.135 |
03:52 ET | 200 | 6.16 |
03:54 ET | 300 | 6.25 |
03:56 ET | 979 | 6.17 |
03:59 ET | 200 | 6.25 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
ESSA Pharma Inc | 274.3M | -10.7x | --- |
Rani Therapeutics Holdings Inc | 278.8M | -4.2x | --- |
Acrivon Therapeutics Inc | 267.1M | -3.1x | --- |
Monte Rosa Therapeutics Inc | 263.2M | -2.1x | --- |
XBiotech Inc | 261.6M | -8.5x | --- |
Inozyme Pharma Inc | 288.9M | -3.5x | --- |
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $274.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 44.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.80 |
EPS | $-0.59 |
Book Value | $3.30 |
P/E Ratio | -10.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.